Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Enlivex Therapeutics Ltd.

An update from Enlivex ( ($ENLV) ) is now available. On July 13, 2026, Enlivex announced that the U.S. Food and Drug Administration granted Regener...

Enlivex Wins FDA RMAT Status for Allocetra in Age-Related Knee Osteoarthritis

Enlivex ( ($ENLV) ) has provided an announcement. On June 22, 2026, Enlivex reported that as of June 20 it held 79,568,550,005 RAIN tokens valued a...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ENLV	$4.64	-0.85%	97.37K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ENLV	$4.64	-0.9%	97.37K
3
4
5
6

ENLV

ENLV

Get Enlivex Therapeutics Ltd. Data in Excel

Get Enlivex Therapeutics Ltd. Data in Excel